t cell receptor, tcr that binds to a hla-a * 02 sllmwitqc complex, tcr anti-cd3 fusion, nucleic acid, expression vector, unnaturally occurring and / or purified and / or occurring cell, , pharmaceutical composition, method of treating a human subject, injectable formulation for administration to a human subject, and method of producing a tcr
ANDREW ALEXANDER KNOX,EMMA ELIZABETH BASTON,FIONA CHESTER,JONATHAN PATRICK LOWTHER,RUTH MARTINEZ HAGUE,VIREN VINUBHAI PATEL
申请号：
BR112018012794
公开号：
BR112018012794A2
申请日:
2016.12.22
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
The present invention relates to t-cell receptors (tcrs) that bind to the hla-a * 02 restricted peptide sllmwitqc derived from the ny-eso-1 cancer antigen. said tcrs may comprise mutations within the alpha and / or beta variable domains relative to a natural ny-eso-1 tcr. The compounds of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.a presente invenção se refere a receptores de célula t (tcrs) que se ligam ao peptídeo restrito sllmwitqc de hla-a*02 derivado do antígeno de câncer ny-eso-1. os ditos tcrs podem compreender mutações dentro dos domínios variáveis alfa e/ou beta em relação a um tcr de ny-eso-1 natural. os tcrs da invenção são particularmente adequados para uso como reagentes imunoterapêuticos inovadores para o tratamento de doença maligna.
